50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$697.33
+9.07 (+1.32%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$681.00
$699.37
50-Day Range
$573.97
$724.32
52-Week Range
$538.01
$754.67
Volume
815,878 shs
Average Volume
917,121 shs
Market Capitalization
$76.02 billion
P/E Ratio
13.92
Dividend Yield
N/A
Price Target
$746.33

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
7.0% Upside
$746.33 Price Target
Short Interest
Healthy
2.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.46mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$35.48 M Sold Last Quarter
Proj. Earnings Growth
7.71%
From $36.32 to $39.12 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

246th out of 1,075 stocks

Pharmaceutical Preparations Industry

103rd out of 532 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Why These 3 Stocks Are Off to Hot September Starts (REGN)
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally.
Trend Tracker for Regeneron Pharmaceuticals REGN
How Are Analyst Ratings Determined?
9 Analysts Have This to Say About Regeneron Pharmaceuticals
Regeneron's Eylea Win Leaves an Elephant in the Room
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2022
Today
9/25/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$746.33
High Stock Price Forecast
$925.00
Low Stock Price Forecast
$575.00
Forecasted Upside/Downside
+7.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
20 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.59%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$80.80 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
99,208,000
Market Cap
$76.02 billion
Optionable
Optionable
Beta
0.29

Social Links


Key Executives

  • Dr. Leonard S. Schleifer M.D.Dr. Leonard S. Schleifer M.D. (Age 69)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $6.47M
  • Dr. George D. Yancopoulos M.D.Dr. George D. Yancopoulos M.D. (Age 62)
    Ph.D., Scientific Founder, Pres, Chief Scientific Officer & Director
    Comp: $6.4M
  • Mr. Robert E. Landry Jr.Mr. Robert E. Landry Jr. (Age 58)
    Exec. VP of Fin. & CFO
    Comp: $1.9M
  • Mr. Joseph J. LaRosaMr. Joseph J. LaRosa (Age 63)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.75M
  • Dr. Andrew J. Murphy Ph.D. (Age 63)
    Exec. VP of Research
    Comp: $1.57M
  • Mr. Daniel P. Van Plew (Age 49)
    Exec. VP and GM of Industrial Operations & Product Supply
    Comp: $1.77M
  • Ms. Patrice Gilooly
    Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. FenimoreMr. Christopher R. Fenimore (Age 51)
    Sr. VP, Head of Accounting & Controller
  • Mr. Gerald Underwood
    Sr. VP of Technical Operations
  • Mr. Bob McCowan
    Sr. VP of IT & Chief Information Officer













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2022?

20 analysts have issued 12 month target prices for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $575.00 to $925.00. On average, they anticipate the company's share price to reach $746.33 in the next year. This suggests a possible upside of 7.0% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 at the start of the year. Since then, REGN stock has increased by 10.4% and is now trading at $697.33.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.53 by $1.24. The biopharmaceutical company earned $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 36.17% and a net margin of 39.97%. Regeneron Pharmaceuticals's quarterly revenue was down 44.4% compared to the same quarter last year. During the same period in the prior year, the company earned $27.97 earnings per share.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.34%), State Street Corp (4.71%), Dodge & Cox (2.09%), Loomis Sayles & Co. L P (1.63%), Price T Rowe Associates Inc. MD (1.55%) and Northern Trust Corp (1.10%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $697.33.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $76.02 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $50.10 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.